Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4985)
All Articles published online
|
Publishing Process of This Article
|
Jun 26, 2021 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Popovic LS, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D. Immunotherapy in the treatment of lymphoma. World J Stem Cells 2021; 13(6): 503-520 [PMID: 34249225 DOI: 10.4252/wjsc.v13.i6.503] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v13/i6/503.htm |
| Number | Citing Articles |
| 1 |
Antonio Cigliola, Gagan Prakash, Roger Li, Karima Oualla, Shilpa Gupta, Ashish M. Kamat, Jad Chahoud, Andrea Necchi, Philippe E. Spiess. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions. Current Oncology Reports 2024; 26(9): 977 doi: 10.1007/s11912-024-01554-1
|
| 2 |
М. Р. Матущак, Г. Л. Панфілова. Pharmaceutical assessment of the rationale of the application of chemotherapy schemes containing immunotherapeutic drugs in the treatment of classical Hodgkin's lymphoma. Farmatsevtychnyi zhurnal 2023; (3): 68 doi: 10.32352/0367-3057.3.23.07
|
| 3 |
Hassan Abolhassani. Hematological Cancer Pathophysiology: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2023; 10: 201 doi: 10.1007/16833_2023_146
|
| 4 |
Sharina C Macapagal, Hayoung Lee, Javaria Abdul Jabbar, Anna Caroline Fjorden, Irene Tresa Joseph, Ramanpreet Kaur, Jihan A Mostafa. Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review. Cureus 2022; doi: 10.7759/cureus.23452
|